C75

C75

• CAS Number: 218137-86-1
• UNSPSC Description: C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM[1][2][3]. C75 is a potent CPT1A activator[5].
• Target Antigen: Fatty Acid Synthase (FASN)
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/C75.html
• Purity: 99.91
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)
• Smiles: O=C(C(C1=C)C(CCCCCCCC)OC1=O)O
• Molecular Weight: 254.32
• References & Citations: [1]Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.|[2]Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity. Chirality. 2013 May;25(5):281-7.|[3]Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5628-33.|[4]Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.|[5] Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1;105(3):550-560.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported